PERTUZUMAB vs TRASTUZUMAB

Compare PERTUZUMAB (PERJETA) and TRASTUZUMAB (Herceptin) — clinical data, side effects, and patient experiences.

PERTUZUMAB

PERJETA · Other

How it works

12.1 Mechanism of Action Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks...

Approved for

locally advanced

inflammatory

or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2

2.2

IntravenousTablet

TRASTUZUMAB

Herceptin · HER2-Targeted Therapy

How it works

12.1 Mechanism of Action The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor rece...

Approved for

1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1

cyclophosphamide

in combination with cisplatin and capecitabine or 5-fluorouracil

IntravenousTablet

Quick Comparison

PERTUZUMABTRASTUZUMAB

Drug Class

Other

HER2-Targeted Therapy

Route

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PERTUZUMAB

Diarrhea

>10%

Fatigue

1-10%

Nausea

1-10%

Hair Loss

1-10%

Vomiting

1-10%

Shortness of Breath

0.1-1%

Fever

0.1-1%

Rash

0.1-1%

TRASTUZUMAB

Diarrhea

>10%

Nausea

1-10%

Hair Loss

1-10%

Fatigue

1-10%

Vomiting

1-10%

Shortness of Breath

1-10%

Fever

0.1-1%

Weakness

0.1-1%

FDA Warnings

PERTUZUMAB

5 WARNINGS AND PRECAUTIONS Infusion-Related Reactions: PERJETA can cause serious infusion reactions, including fatal events: Monitor for signs and symptoms
Patients who received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF or left ventricular dysfunction
Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy
In an animal reproduction study, administration of pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death at exposures 2

TRASTUZUMAB

5 WARNINGS AND PRECAUTIONS Exacerbation of Chemotherapy-Induced Neutropenia
1 Cardiomyopathy Herceptin can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ]
Patients who receive anthracycline after stopping Herceptin may also be at increased risk of cardiac dysfunction [see Drug Interactions (7) and Clinical Pharmacology (12
2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology

Clinical Trial Data

No head-to-head clinical studies found for PERTUZUMAB vs TRASTUZUMAB.

PERTUZUMAB vs TRASTUZUMAB: What You Should Know

Key Differences

PERTUZUMAB is a Other, while TRASTUZUMAB belongs to the HER2-Targeted Therapy class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Safety Considerations

PERTUZUMAB carries 4 FDA warnings. TRASTUZUMAB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LETROZOLE vs TRASTUZUMAB→LETROZOLE vs PERTUZUMAB→ANASTROZOLE vs TRASTUZUMAB→ANASTROZOLE vs PERTUZUMAB→EXEMESTANE vs TRASTUZUMAB→EXEMESTANE vs PERTUZUMAB→

Loading comparison data...

PERTUZUMAB vs TRASTUZUMAB

Compare PERTUZUMAB (PERJETA) and TRASTUZUMAB (Herceptin) — clinical data, side effects, and patient experiences.

PERTUZUMAB

PERJETA · Other

How it works

12.1 Mechanism of Action Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks...

Approved for

locally advanced

inflammatory

or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2

2.2

IntravenousTablet

TRASTUZUMAB

Herceptin · HER2-Targeted Therapy

How it works

12.1 Mechanism of Action The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor rece...

Approved for

1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1

cyclophosphamide

in combination with cisplatin and capecitabine or 5-fluorouracil

IntravenousTablet

Quick Comparison

PERTUZUMABTRASTUZUMAB

Drug Class

Other

HER2-Targeted Therapy

Route

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PERTUZUMAB

Diarrhea

>10%

Fatigue

1-10%

Nausea

1-10%

Hair Loss

1-10%

Vomiting

1-10%

Shortness of Breath

0.1-1%

Fever

0.1-1%

Rash

0.1-1%

TRASTUZUMAB

Diarrhea

>10%

Nausea

1-10%

Hair Loss

1-10%

Fatigue

1-10%

Vomiting

1-10%

Shortness of Breath

1-10%

Fever

0.1-1%

Weakness

0.1-1%

FDA Warnings

PERTUZUMAB

5 WARNINGS AND PRECAUTIONS Infusion-Related Reactions: PERJETA can cause serious infusion reactions, including fatal events: Monitor for signs and symptoms
Patients who received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF or left ventricular dysfunction
Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy
In an animal reproduction study, administration of pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death at exposures 2

TRASTUZUMAB

5 WARNINGS AND PRECAUTIONS Exacerbation of Chemotherapy-Induced Neutropenia
1 Cardiomyopathy Herceptin can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy ]
Patients who receive anthracycline after stopping Herceptin may also be at increased risk of cardiac dysfunction [see Drug Interactions (7) and Clinical Pharmacology (12
2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology

Clinical Trial Data

No head-to-head clinical studies found for PERTUZUMAB vs TRASTUZUMAB.

PERTUZUMAB vs TRASTUZUMAB: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.